BeiGene
China's largest oncology biotech by revenue. Brukinsa (zanubrutinib), a next-generation BTK inhibitor, is approved in 70+ countries competing directly with AstraZeneca's Calquence and AbbVie's Imbruvica globally. Dual-listed NASDAQ (BGNE) and HKEX (6160.HK). Significant US and EU commercial presence.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Selected active clinical trials
Phase 2 · Recruiting · MSI-H/dMMR Solid Tumors
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström MacroglobulinemiaNA · Recruiting · Waldenstrom Macroglobulinemia
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-DegraderPhase 1 · Recruiting · B-cell Malignancy
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLLPhase 3 · Active Not Recruiting · Chronic Lymphocytic Leukemia
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)Phase 3 · Active Not Recruiting · Non Small Cell Lung Cancer
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian CancerPhase 3 · Active Not Recruiting · Ovarian Cancer
Selected patent records
zanubrutinib · Expires 2034-04-22
US 11142528zanubrutinib · Expires 2034-04-22
US 9447106zanubrutinib · Expires 2034-04-22
US 10927117zanubrutinib · Expires 2037-08-15
US 11591340zanubrutinib · Expires 2037-08-15
US 11851437zanubrutinib · Expires 2037-08-15
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/beigene/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.